Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Sarcoma 39Lymphoma 38Lymphoma, Large B-Cell, Diffuse 28Lymphoma, Non-Hodgkin 22Osteosarcoma 15Burkitt Lymphoma 14Hodgkin Disease 13Testicular Neoplasms 11Recurrence 9Leukemia 9Neuroectodermal Tumors, Primitive, Peripheral 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Teratoma 7Ovarian Neoplasms 7Lymphoma, Mantle-Cell 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Germ Cell Tumor 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Carcinoma, Embryonal 6Breast Neoplasms 6Rhabdomyosarcoma 5Lymphoma, Large-Cell, Anaplastic 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms, Germ Cell and Embryonal 4Lymphoma, B-Cell 4

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡